Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Snakes (aka Chutes) and Ladders – failures and opportunities
Posted on October 13th, 2017 by Dr Andrew A. Parsons in Pharma R&D
If there ever was a children’s game that would help prepare the next generation of pharmaceutical R&D scientists and researchers, it would be Snakes and Ladders (Chutes and Ladders in the US). Continue reading “Snakes (aka Chutes) and Ladders – failures and opportunities” »
Using Machine Learning for Identifying and Classifying Patient Groups
Posted on August 14th, 2017 by Dr Andrew A. Parsons in Pharma R&D
To maximize value to payers, patients, and practitioners, pharma R&D wants to ensure that new medicines are given to the right patient, at the right time and at the right dose. To do this appropriately, we need ways to classify or diagnose patient groups.
Continue reading “Using Machine Learning for Identifying and Classifying Patient Groups” »
Hopes, Issues, and Concerns in Tackling the Challenge of Dementia
Posted on July 24th, 2017 by Dr Andrew A. Parsons in Pharma R&D
With recent failures of large Phase 3 studies targeting the amyloid pathways, there is perhaps a need for some good news for scientists, clinicians, health services and the general public. Recently, there was some good news in the media. Continue reading “Hopes, Issues, and Concerns in Tackling the Challenge of Dementia” »
Start-Up Spotlight: Innovative NeuroTechnologies, Inc.
Posted on January 27th, 2017 by Betsy Davis in Pharma R&D
We’re shining a light this week on Innovative NeuroTechnologies, Inc., based in sunny California. Founder, President & CEO Shawn Mojtahedian, Ph.D. talks about how the biotech is focusing on unmet need for a spectrum of disorders Continue reading “Start-Up Spotlight: Innovative NeuroTechnologies, Inc.” »